Updated 07 August 2015

FDA approves new type 2 diabetes drug

The FDA has approved a new type 2 diabetes drug called Tanzeum which is injected once a week. Tanzeum can be used in conjunction with existing treatments.


Millions of Americans with type 2 diabetes have a new treatment option with the US Food and Drug Administration's approval of a once-weekly injectable drug, Tanzeum.

The FDA described Tanzeum (albiglutide) as a "glucagon-like peptide-1 (GLP-1) receptor agonist – a hormone that helps normalise patients' blood sugar levels.

Tanzeum "can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes," Dr Curtis Rosebraugh, director of the Office of Drug Evaluation II in the FDA's Centre for Drug Evaluation and Research, said in an agency news release.

The FDA's approval of the drug was based on eight clinical trials that included more than 2 000 people with type 2 diabetes. Those who took Tanzeum showed improvements in blood sugar control. The drug has also been studied for use in combination with other diabetes medications such as metformin, glimepiride, pioglitazone (Actos) and insulin.

Side effects of Tanzeum

The most common side effects seen with Tanzeum were nausea and/or reactions at the site of injection, the FDA said.

The drug, which is manufactured by GlaxoSmithKline, is not approved to treat Type 1 diabetes, the FDA noted.

The drug will carry a boxed warning stating that the use of some GLP-1 receptor agonists has been associated with thyroid tumours in rodents. The FDA said Tanzeum should not be prescribed for patients with a personal or family history of a type of thyroid cancer called medullary thyroid carcinoma (MTC), or for patients with Multiple Endocrine Neoplasia syndrome type 2. Patients with this disease have tumours in more than one gland in their body and are at increased risk for MTC.

Dr Spyros Mezitis is an endocrinologist at Lenox Hill Hospital in New York City. He said Tanzeum joins a list of other approved injectable diabetes medicines, including Victoza (liraglutide), Byetta (exenatide) and Bydureon (exenatide extended release).

"Post-marketing clinical trials are planned to examine cardiovascular effects, use in paediatric patients, and possible increase in pancreatitis or medullary thyroid cancer," Mezitis said. "The results of these clinical trials will determine which GLP-1 agonists will be more useful" to patients.

According to the FDA, about 24 million people in the United States have type 2 diabetes, which accounts for more than 90% of all diabetes cases diagnosed in the United States. Over time, the high blood sugar levels produced by diabetes can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage.

Read more:
New diabetes drug promising
Diabetes drug improves memory

Diabetes drug, weight loss linked

Copyright © 2016 HealthDay. All rights reserved.


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.